Choosing the right animal species is a crucial element to developing a nonclinical strategy for toxicology studies because if the drug is pharmacologically active in said species, it can predict any adverse effects that drug may have in patients. So what happens when there isn’t a relevant species available?
This webinar will delve into the various approaches when developing nonclinical strategies for therapeutics being used in foreign targets, such as bacterial, viral, and non-expressing human targets.
Scientific Moderator and Presenters
Peter Gaskin, PhD, ERT, MTOPRA
Senior Director of Scientific Advisory Services
Jenny Sims, PhD
Founder and Director
Magnus Nicholson, FRSC, FRSM
Chief Operating Officer
View the other webinars in the series:
- IND Perspectives: Approaching Drug Development from Multiple Angles (View On Demand)
- The Future of Nonclinical Studies in the Age of COVID-19 (September 28)
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.